ISSN (O): 2349-5332
CODEN: IRJPHY

EVALUATING THE HEPATIC SAFETY OF ALLOPURINOL IN INTENSIVE CARE UNIT PATIENTS: A COMPREHENSIVE RETROSPECTIVE STUDY AT QUEEN ALIA HEART INSTITUTE, JORDAN

Ghadeer Majed AlJamaeen*, Hala Anwar Altarawneh, Basma Hail Al Zabin, Tasnim Ayman Al-Omari, Shatha Nayef Alsyouf.

Pharmacist, Royal Medical Services, Jordan.

Submitted on: 13.06.2024;	**Revised on:** 14.06.2024;	**Accepted on:** 15.06.2024

ABSTRACT

1. Introduction: Allopurinol, a widely prescribed xanthine oxidase inhibitor for the treatment of hyperuricemia and its complications, such as gout, is occasionally associated with hepatotoxic effects. Understanding these effects is particularly crucial in vulnerable populations, such as those in intensive care (ICU) settings where multiple comorbidities and the use of various medications might alter drug metabolism and efficacy. Despite the known benefits of allopurinol in managing elevated uric acid levels, the specifics of its hepatic impact remain less well-documented in the ICU patient cohort.

2. Objective: This study aims to evaluate the hepatic safety of allopurinol in patients admitted to the ICU at Queen Alia Heart Institute, providing a clearer understanding of its liver function profiles in a critically ill population. By documenting and analyzing liver enzyme levels and total bilirubin in these patients, this research seeks to establish whether allopurinol contributes to significant hepatic disturbances in this particular clinical context.

3. Methodology: A retrospective review will be conducted on the medical electronic records of 130 patients admitted to the ICU of Queen Alia Heart Institute who received allopurinol between 2019 and 2022. Liver function tests, including AST (Aspartate Aminotransferase), ALT (Alanine Aminotransferase), ALP (Alkaline Phosphatase), total bilirubin and demographic data (age, sex), will be collected from patient records. This study will analyze these data using descriptive statistics to determine the range and average values of liver enzymes and bilirubin and demographic analysis will be performed to explore correlations between patient characteristics and changes in liver function tests, aiming to identify any patterns or demographic factors that might influence the drug's hepatotoxic potential with the presence of clinically significant alterations in liver function tests served as the primary outcome measure to assess hepatotoxic potential.

KEYWORDS: Allopurinol, Liver Function Tests, ICU Patients, Hepatotoxicity, Retrospective Study, Jordanian Medical Services.

Corresponding author: Ghadeer Majed AlJamaeen
E-mail: gh.jam3ani86@gmail.com,
Mobile No: 00962799015406

Indian Research Journal of Pharmacy and Science; 39(2024)3073-3077;
Journal Home Page: https://www.irjps.in

1. INTRODUCTION

Xanthine oxidase inhibitors like allopurinol are commonly used to treat and prevent diseases like gout and some forms of kidney stones that are brought on by high uric acid levels. Its effectiveness in lowering the production of uric acid has been demonstrated, and this is important in the treatment of these ailments. Allopurinol has been linked to a number of side effects, one of which liver dysfunction has sparked serious clinical concerns, despite its many therapeutic advantages. Given the liver's function in drug metabolism and detoxification, this association is especially intriguing[1].

The possible hepatotoxic effects of allopurinol are a concern in clinical practice, particularly in patients receiving concurrent hepatotoxic drugs or those with pre-existing liver problems. Though it happens infrequently, hepatotoxicity can range from moderate liver enzyme increases to serious situations including abrupt liver failure. Though the exact processes underlying allopurinol-induced liver injury are unknown, direct toxicity and hypersensitivity reactions are considered to be involved. Direct toxicity may also be mediated through oxypurinol, an allopurinol metabolite[1,2].

Knowing how allopurinol affects liver enzymes and overall liver health is crucial since liver function is so critical and because the drug is used widely. This is particularly true in environments like intensive care units (ICUs), where patients may be more susceptible to negative outcomes. ICU patients frequently have complicated medical histories, including impaired liver function, which may change their risk of pharmaceutical side effects.

Many patients with cardiovascular disorders are treated at the Queen Alia Heart Institute, which is part of the Jordanian Medical Services. A significant proportion of these patients also have conditions that require the use of allopurinol. In this study, 130 ICU patients treated at this institute between 2019 and 2022 will be used as a sample, and the effects of allopurinol on liver function will be investigated. The study aims to shed light on the hepatic safety profile of allopurinol in a monitored acute care environment by concentrating on this demographic.

In order to achieve this, we will go over the patients' medical records, paying particular attention to liver function tests like total bilirubin levels, alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST). These markers offer a useful evaluation tool for identifying hepatic injury since they give a comprehensive picture of the integrity and function of the liver. The results of this investigation are intended to add significant information to the body of knowledge regarding the hepatic effects of allopurinol, which may help to direct clinical procedures in intensive care units across the globe.

2. METHOD

A retrospective evaluation of the medical records of patients admitted to the intensive care unit (ICU) and treated with allopurinol between 2019 and 2022 was employed in this study. Year of admission, gender, age, and results of liver function tests (AST, ALT, ALP, and total bilirubin levels) were among the information gathered. And patients who were hospitalized to the Queen Alia Heart Institute's ICU between 2019 and 2022, those who received allopurinol throughout their stay, and the availability of comprehensive liver function test results during allopurinol medication were the inclusion criteria.

Data Analysis Approach: Descriptive statistics was used to calculate basic statistical measures for liver function tests in order to understand the central tendency and dispersion of the enzyme levels. Subgroup analysis was then used to separate the data based on age and sex groups in order to find any differences in the effects of allopurinol on these subgroups.

Ethical Considerations: Regarding patient data confidentiality and the ethical handling of patient information, the study complied with ethical criteria to the full. To protect privacy and uphold confidentiality, all patient identifiers were anonymized.

Quality Control and Data Integrity: Several tests were made to guarantee the data's integrity and authenticity. Errors in data entry, record consistency between years, and data completeness were all closely investigated. Cross-referencing patient records was done to resolve any disparities that were discovered during the data verification process.

Through adherence to this methodology, the study sought to offer a thorough and dependable examination of the hepatic effects of allopurinol in Queen Alia Heart Institute ICU patients, thereby providing important insights into the safe

administration of this medication in patient populations at high risk.

3. RESULTS

The study examined liver function tests from 130 ICU patients treated with allopurinol between 2019 and 2022 who were admitted to Queen Alia Heart Institute. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total bilirubin were among the parameters measured as part of the liver function tests. The outcomes were recorded as follows:

Table (1): levels of liver function tests among study participants

Liver Function Test	Lowest	Highest	Range
AST (U/L)	22.78	31.96	22.78 U/L - 31.96 U/L
ALT (U/L)	17.48	17.48	17.48 U/L - 27.47 U/L
ALP (U/L)	30.83	55.98	30.83 U/L - 55.98 U/L
Total Bilirubin (mg/dL)	0.61	1.29	0.61 mg/dL - 1.29 mg/dL

The range of measurements for each liver function parameter among ICU patients receiving allopurinol treatment during the study period is effectively displayed in this table (1).

Distribution of Liver Function Test Results by Gender: The data subset showed the following distribution among male and female patients (table 2):

Table (2):Distribution of Liver Function Test Results by Gender

Gender	Liver Function Test	Range
Male Patients	AST (U/L)	22.78- 31.96
	ALT (U/L)	17.47- 27.34
	ALP (U/L)	35.18- 55.98
	Total Bilirubin (mg/dL)	0.61- 1.29
Female Patients	AST (U/L)	23.75- 31.27
	ALT (U/L)	18.27- 26.74
	ALP (U/L)	30.83 - 55.02
	Total Bilirubin (mg/dL)	0.68- 1.29

Age-Related Observations:

The patients under treatment ranged in age from 15 to 92, demonstrating a wide range of allopurinol use in a therapeutic context across various age groups.

The liver function test results show a stable range of values without any extreme outliers, indicating that allopurinol administration did not cause any immediate hepatotoxic consequences in this patient group.

4. DISCUSSION

This study analyzed data from liver function tests (AST, ALT, ALP, and total bilirubin) obtained from 130 patients over a four-year period in order to assess the effect of allopurinol on liver function among ICU patients at the Queen Alia Heart Institute. The findings imply that the administration of allopurinol did not have a major hepatotoxic effect because the liver function test values in this patient sample stayed within a very limited range.

Stability of Liver Function Tests: The information showed that the total bilirubin levels remained between 0.61 and 1.29 mg/dL, the AST levels varied between 22.78 and 31.96 U/L, the ALT levels between 17.48 and 27.47 U/L, and the ALP levels between 30.83 and 55.98 U/L. These levels are often regarded as being within the normal ranges for these tests, or at most slightly higher, suggesting that allopurinol is not the cause of any acute liver damage or dysfunction.

Analysis by Gender: The gender-specific analysis of liver function test results revealed comparable ranges in both male and female patients. This is a noteworthy finding as it implies that gender has no discernible impact on the hepatic response to allopurinol in this particular context. This is in line with allopurinol's pharmacological profile, which does not appear to have any effects or metabolic pathways that are specific to gender[3].

Age-Related Considerations: The study participants' age range of 15 to 92 years offers important insight into the safety of allopurinol over a wide age range. The consistent results of liver function tests over this wide age range support the idea that age and gender have no effect on the hepatic adverse reactions to allopurinol. This is especially significant since alterations in liver function brought on by aging might impact how different medicines are metabolized.

Clinical Implications: These results are encouraging from a clinical standpoint, indicating that allopurinol can be taken in a critically ill group without risk to liver function. This is especially important in the intensive care unit (ICU) context, as patients frequently have complicated drug schedules that may interact with allopurinol and may have several comorbidities.

Comparative Analysis: The study's findings regarding the stability of liver enzyme levels are in opposition to the occasional reports of hepatotoxicity caused by allopurinol in other contexts. These disparities could be explained by variations in patient groups, underlying medical issues, or concurrent usage of other drugs. It draws attention to the significance of context in evaluating medication safety and the possible contribution of close observation to reducing hazards related to drug therapy.

Conclusion: The results underline the necessity of routinely monitoring liver function tests as part of comprehensive patient care, but they also justify the continued use of allopurinol in comparable clinical contexts. Subsequent investigations may delve into longitudinal patterns or endeavor to ascertain credible biomarkers that could anticipate sensitivity to hepatotoxicity associated with allopurinol in susceptible demographics.

In summary, this discussion adds a layer of safety assurance for the use of allopurinol in addressing disorders associated with high uric acid levels by supporting the claim that, when administered under intensive medical monitoring in an ICU context, it does not significantly contribute to liver damage.

5. CONCLUSIONS

The examination of liver function test results from 130 critically ill ICU patients treated with allopurinol at Queen Alia Heart Institute between 2019 and 2022 offers important new information on the drug's hepatic safety in this population. Allopurinol did not appear to cause hepatotoxicity in the settings seen in this intensive care unit (ICU) because levels of AST, ALT, ALP, and total bilirubin stayed within widely recognized clinical ranges over the study period.

Stable Liver Enzyme Levels: The liver enzymes AST, ALT, and ALP, together with total bilirubin levels, showed very little variation and remained within safe ranges; supporting the idea that allopurinol can be given to ICU patients safely as long as close supervision is provided.

Demographic Insights: The results of the study showed that there were no appreciable variations in liver function tests according to age or gender throughout a broad age range. This suggests that the hepatic safety of allopurinol can be widely applied to a variety of patient demographics in the intensive care unit.

Clinical Implications: As long as patients are carefully chosen and well observed, these findings reassure doctors that allopurinol can be used in an ICU context without undue risk of acute liver injury. This is especially important because intensive care unit patients frequently need complicated, multiple regimens that may interfere with allopurinol.

Further Considerations:

Even with the encouraging statistics, ongoing caution is advised. Liver function tests should continue to be routinely monitored; this is especially important in critical care settings where patients may have unstable health and are frequently exposed to a variety of pharmaceutical

drugs. Prospective research would also be helpful in confirming these results and examining the processes underlying the infrequent instances of allopurinol-induced hepatotoxicity that have been documented in various contexts.

All things considered, this work adds to the body of data indicating that allopurinol is a safe treatment option for ICU patients hyperuricemia, with no appreciable hepatotoxic consequences noted. But it also emphasizes how crucial it is to conduct regular assessments and exercise cautious medical supervision when administering any pharmacologic treatment, especially to a fragile group like patients in the intensive care unit.

LIMITATIONS OF THE STUDY

The retrospective design of the study, its dependence on accessible medical information, and the lack of a control group receiving no allopurinol treatment were its main limitations. To validate these results, more prospective research with larger sample sizes and controlled environments are advised.

ACKNOWLEDGMENTS

We appreciate the collaboration and support provided by the Queen Alia Heart Institute staff during the data gathering and processing process. We are very grateful to the Jordanian Medical Services for allowing us to use their medical information records for research.

REFERENCES:

1. Chen C, Chung W, Lin Y, Chang C, Chang S. Risk of Severe Adverse Reactions Related to Allopurinol and Febuxostat in Asians. *Value Health*. 2018;21:S106. doi:10.1016/j.jval.2018.07.801
2. Zhang S, Xie Q, Xie S, et al. The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): a network meta-analysis of randomized trials. *Pharmacotherapy*. 2021;41(9):781–791. doi:10.1002/phar.2609
3. Iqbal U, Siddiqui HU, Anwar H, Chaudhary A, Quadri AA. Allopurinol-induced granulomatous hepatitis: a case report and review of literature. *J Investig Med High Impact Case Rep*. 2017;5(3). doi:10.1177/2324709617728302
4. Singh JA, Gaffo A. Gout epidemiology and comorbidities. *Semin Arthritis Rheum*. 2020;50(3):S11–S16. doi:10.1016/j.semarthrit.2020.04.008
5. Neilson J, Bonnon A, Dickson A. Gout: diagnosis and management NICE guideline; 2022. Available from: www.nice.org.uk/guidance/ng219. Accessed September 8, 2023.
6. Hainer BL, Matheson E, Wilkes RT *Diagnosis, Treatment, and Prevention of Gout*. Vol 90; 2014. Available from: www.aafp.org/afp. Accessed Septe mber 8, 2023.
7. Suzuki S, Yoshihisa A, Yokokawa T, et al. Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial. *J Int Med Res*. 2021;49(12):030006052110627. doi:10.1177/03000605211062770
8. Kannangara DRW, Graham GG, Wright DFB, et al. Individualising the dose of allopurinol in patients with gout. *Br J Clin Pharmacol*. 2017;83(9):2015–2026. doi:10.1111/bcp.13307
9. Singh JA, Richards JS, Chang E, Toupin-April K, Barton JL. Shared decision-making in gout treatment: a national study of rheumatology provider opinion and practice. *Clin Rheumatol*. 2021;40(2):693–700. doi:10.1007/s10067-020-05421-9

CONFLICT OF INTEREST REPORTED: NIL; SOURCE OF FUNDING: NONE REPORTED